Compare KOS & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOS | GLPG |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2011 | N/A |
| Metric | KOS | GLPG |
|---|---|---|
| Price | $3.08 | $27.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $1.91 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 18.6M | 141.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,352,000.00 | N/A |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $24.74 |
| 52 Week High | $3.17 | $37.78 |
| Indicator | KOS | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 63.08 | 31.88 |
| Support Level | $1.62 | N/A |
| Resistance Level | $3.09 | $34.04 |
| Average True Range (ATR) | 0.15 | 0.50 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 93.12 | 18.46 |
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.